However, some lipid-lowering drugs, such as PCSK9 inhibitors, have various effects, including reducing the risk of cancer (Carter et al., 2020) and increasing the risk of type 2 diabetes (Rao et al., 2018). This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.